China Medicine Revenue vs. Total Debt
| CHME Stock | USD 0.0002 0.0001 100.00% |
For China Medicine profitability analysis, we use financial ratios and fundamental drivers that measure the ability of China Medicine to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well China Medicine utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between China Medicine's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of China Medicine over time as well as its relative position and ranking within its peers.
China |
China Medicine Total Debt vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining China Medicine's current stock value. Our valuation model uses many indicators to compare China Medicine value to that of its competitors to determine the firm's financial worth. China Medicine is rated below average in revenue category among its peers. It also is rated below average in total debt category among its peers making up about 0.06 of Total Debt per Revenue. The ratio of Revenue to Total Debt for China Medicine is roughly 15.99 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the China Medicine's earnings, one of the primary drivers of an investment's value.China Revenue vs. Competition
China Medicine is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 494.72 Billion. China Medicine adds roughly 64.75 Million in revenue claiming only tiny portion of equities under Health Care industry.
China Total Debt vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
China Medicine |
| = | 64.75 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
China Medicine |
| = | 4.05 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
China Total Debt vs Competition
China Medicine is rated below average in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 16.62 Billion. China Medicine adds roughly 4.05 Million in total debt claiming only tiny portion of equities under Health Care industry.
China Medicine Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in China Medicine, profitability is also one of the essential criteria for including it into their portfolios because, without profit, China Medicine will eventually generate negative long term returns. The profitability progress is the general direction of China Medicine's change in net profit over the period of time. It can combine multiple indicators of China Medicine, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
China Medicine Corporation produces and distributes prescription and over the counter drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. China Medicine Corporation was founded in 2005 and is based in Guangzhou, China. CHINA MEDICINE operates under Medical Distribution classification in the United States and is traded on OTC Exchange. It employs 281 people.
China Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on China Medicine. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of China Medicine position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the China Medicine's important profitability drivers and their relationship over time.
Use China Medicine in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if China Medicine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in China Medicine will appreciate offsetting losses from the drop in the long position's value.China Medicine Pair Trading
China Medicine Pair Trading Analysis
The ability to find closely correlated positions to China Medicine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace China Medicine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back China Medicine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling China Medicine to buy it.
The correlation of China Medicine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as China Medicine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if China Medicine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for China Medicine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your China Medicine position
In addition to having China Medicine in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Healthcare Funds Thematic Idea Now
Healthcare Funds
Funds or Etfs investing in medical and healthcare goods or services as well as hospital management or maintenance organizations. The Healthcare Funds theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Healthcare Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in China Pink Sheet
To fully project China Medicine's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of China Medicine at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include China Medicine's income statement, its balance sheet, and the statement of cash flows.